CC0651

Drug screening technologies are experimental and computational strategies used to identify small molecules or chemical probes that modulate a defined molecular target, signaling pathway, cellular phenotype, disease model, or patient-derived response profile. High-throughput screening tests many compounds in miniaturized assay formats, while quantitative high-throughput screening tests compounds across concentration ranges so that potency and efficacy can be inferred from concentration-response behavior rather than from a single-point signal. The core biological function of a drug-screening strategy is to connect compound exposure with measurable pathway activity, target modulation, cell-state change, viability, cytotoxicity, morphology, or disease-relevant phenotype. Assay performance must be evaluated before screening because hit identification depends on the separation between positive and negative controls, control variability, plate effects, outliers, and the statistical framework

Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.